| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
106.27(B) |
| Last
Volume: |
12,453,498 |
Avg
Vol: |
12,080,229 |
| 52
Week Range: |
$39.66 - $63.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 10.3 |
| Insider 3/6 Months : 18.7 |
|
| Guru Rank Number : 243 |
| Guru Rank Value : 6.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,250 |
8,073 |
9,903 |
23,474 |
| Total Buy Value |
$202,215 |
$412,311 |
$512,366 |
$1,185,360 |
| Total People Bought |
1 |
2 |
2 |
3 |
| Total Buy Transactions |
1 |
3 |
4 |
7 |
| Total Shares Sold |
97 |
97 |
797 |
19,515 |
| Total Sell Value |
$3,702 |
$3,702 |
$42,633 |
$1,189,030 |
| Total People Sold |
1 |
1 |
2 |
4 |
| Total Sell Transactions |
1 |
1 |
2 |
4 |
| End Date |
2025-03-20 |
2024-12-17 |
2024-06-18 |
2023-06-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Boerner Christopher S. |
Chief Executive Officer |
• • – |
2025-06-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
62,719 |
125,439 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2025-06-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
62,719 |
0 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2025-06-03 |
4 |
GA |
$0.00 |
$0 |
I/I |
62,720 |
62,720 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2025-06-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
62,720 |
62,719 |
|
- |
|
| Short Bartie Wendy |
EVP, Corporate Affairs |
• – – |
2025-06-03 |
4 |
D |
$48.09 |
$160,332 |
D/D |
(3,334) |
4,706 |
|
- |
|
| Short Bartie Wendy |
EVP, Corporate Affairs |
• – – |
2025-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,040 |
8,040 |
|
- |
|
| Hickey Benjamin |
President, RayzeBio Org. |
• – – |
2025-05-09 |
4 |
S |
$38.01 |
$3,702 |
I/I |
(97) |
0 |
|
-7% |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2025-04-25 |
4 |
B |
$47.58 |
$202,215 |
D/D |
4,250 |
83,513 |
2.74 |
4% |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2025-04-01 |
4 |
D |
$59.55 |
$100,759 |
D/D |
(1,692) |
13,797 |
|
- |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,306 |
15,489 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2025-03-10 |
4 |
D |
$63.11 |
$1,321,208 |
D/D |
(20,935) |
223,379 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2025-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,171) |
235,674 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
69,517 |
252,608 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2025-03-10 |
4 |
D |
$63.11 |
$1,117,678 |
D/D |
(17,710) |
364,296 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2025-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,097) |
374,659 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
48,718 |
386,496 |
|
- |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2025-03-10 |
4 |
D |
$63.11 |
$423,531 |
D/D |
(6,711) |
16,102 |
|
- |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2025-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,333) |
20,660 |
|
- |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,150 |
26,937 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2025-03-10 |
4 |
D |
$63.11 |
$1,013,294 |
D/D |
(16,056) |
79,263 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2025-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,711) |
88,495 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
44,098 |
99,040 |
|
- |
|
| Hoch Lynelle |
President, Cell Therapy Org. |
• – – |
2025-03-10 |
4 |
D |
$63.11 |
$141,871 |
D/D |
(2,248) |
4,711 |
|
- |
|
| Hoch Lynelle |
President, Cell Therapy Org. |
• – – |
2025-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,213) |
6,070 |
|
- |
|
| Hoch Lynelle |
President, Cell Therapy Org. |
• – – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,446 |
7,920 |
|
- |
|
836 Records found
|
|
Page 1 of 34 |
|
|
1.43 (2.94%) 
